Overview

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants

Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of capivasertib on the pharmacokinetics of oral dextromethorphan in healthy participants.
Phase:
PHASE1
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Parexel
Treatments:
capivasertib
Dextromethorphan